ID   NPR1_ARATH              Reviewed;         593 AA.
AC   P93002; O04742;
DT   05-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   18-JUN-2025, entry version 189.
DE   RecName: Full=Regulatory protein NPR1 {ECO:0000303|PubMed:9019406};
DE   AltName: Full=BTB/POZ domain-containing protein NPR1 {ECO:0000303|PubMed:9019406};
DE   AltName: Full=Non-inducible immunity protein 1 {ECO:0000303|PubMed:9090885};
DE            Short=Nim1 {ECO:0000303|PubMed:9090885};
DE   AltName: Full=Nonexpresser of PR genes 1 {ECO:0000303|PubMed:9019406};
DE   AltName: Full=Salicylic acid insensitive 1 {ECO:0000303|PubMed:9002272};
DE            Short=Sai1 {ECO:0000303|PubMed:9002272};
GN   Name=NPR1 {ECO:0000303|PubMed:9019406};
GN   Synonyms=NIM1 {ECO:0000303|PubMed:9090885}, SAI1
GN   {ECO:0000303|PubMed:9002272};
GN   OrderedLocusNames=At1g64280 {ECO:0000312|Araport:AT1G64280};
GN   ORFNames=F15H21.6 {ECO:0000312|EMBL:AAG51705.1};
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC   rosids; malvids; Brassicales; Brassicaceae; Camelineae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND MUTAGENESIS OF CYS-150 AND
RP   HIS-334.
RC   STRAIN=cv. Columbia;
RX   PubMed=9019406; DOI=10.1016/s0092-8674(00)81858-9;
RA   Cao H., Glazebrook J., Clarke J.D., Volko S., Dong X.;
RT   "The Arabidopsis NPR1 gene that controls systemic acquired resistance
RT   encodes a novel protein containing ankyrin repeats.";
RL   Cell 88:57-63(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS ASN-93; THR-96; ALA-108 DEL;
RP   TRP-268 AND PRO-406, AND MUTAGENESIS OF HIS-300 AND ARG-432.
RC   STRAIN=cv. Columbia, and cv. Wassilewskija;
RX   PubMed=9090885; DOI=10.1105/tpc.9.3.425;
RA   Ryals J., Weymann K., Lawton K., Friedrich L., Ellis D., Steiner H.-Y.,
RA   Johnson J., Delaney T.P., Jesse T., Vos P., Uknes S.;
RT   "The Arabidopsis NIM1 protein shows homology to the mammalian transcription
RT   factor inhibitor I kappa B.";
RL   Plant Cell 9:425-439(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   PubMed=11130712; DOI=10.1038/35048500;
RA   Theologis A., Ecker J.R., Palm C.J., Federspiel N.A., Kaul S., White O.,
RA   Alonso J., Altafi H., Araujo R., Bowman C.L., Brooks S.Y., Buehler E.,
RA   Chan A., Chao Q., Chen H., Cheuk R.F., Chin C.W., Chung M.K., Conn L.,
RA   Conway A.B., Conway A.R., Creasy T.H., Dewar K., Dunn P., Etgu P.,
RA   Feldblyum T.V., Feng J.-D., Fong B., Fujii C.Y., Gill J.E., Goldsmith A.D.,
RA   Haas B., Hansen N.F., Hughes B., Huizar L., Hunter J.L., Jenkins J.,
RA   Johnson-Hopson C., Khan S., Khaykin E., Kim C.J., Koo H.L.,
RA   Kremenetskaia I., Kurtz D.B., Kwan A., Lam B., Langin-Hooper S., Lee A.,
RA   Lee J.M., Lenz C.A., Li J.H., Li Y.-P., Lin X., Liu S.X., Liu Z.A.,
RA   Luros J.S., Maiti R., Marziali A., Militscher J., Miranda M., Nguyen M.,
RA   Nierman W.C., Osborne B.I., Pai G., Peterson J., Pham P.K., Rizzo M.,
RA   Rooney T., Rowley D., Sakano H., Salzberg S.L., Schwartz J.R., Shinn P.,
RA   Southwick A.M., Sun H., Tallon L.J., Tambunga G., Toriumi M.J., Town C.D.,
RA   Utterback T., Van Aken S., Vaysberg M., Vysotskaia V.S., Walker M., Wu D.,
RA   Yu G., Fraser C.M., Venter J.C., Davis R.W.;
RT   "Sequence and analysis of chromosome 1 of the plant Arabidopsis thaliana.";
RL   Nature 408:816-820(2000).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=cv. Columbia;
RX   PubMed=27862469; DOI=10.1111/tpj.13415;
RA   Cheng C.Y., Krishnakumar V., Chan A.P., Thibaud-Nissen F., Schobel S.,
RA   Town C.D.;
RT   "Araport11: a complete reannotation of the Arabidopsis thaliana reference
RT   genome.";
RL   Plant J. 89:789-804(2017).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RX   PubMed=14593172; DOI=10.1126/science.1088305;
RA   Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J., Southwick A.M.,
RA   Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F., Karlin-Newmann G.,
RA   Liu S.X., Lam B., Sakano H., Wu T., Yu G., Miranda M., Quach H.L.,
RA   Tripp M., Chang C.H., Lee J.M., Toriumi M.J., Chan M.M., Tang C.C.,
RA   Onodera C.S., Deng J.M., Akiyama K., Ansari Y., Arakawa T., Banh J.,
RA   Banno F., Bowser L., Brooks S.Y., Carninci P., Chao Q., Choy N., Enju A.,
RA   Goldsmith A.D., Gurjal M., Hansen N.F., Hayashizaki Y., Johnson-Hopson C.,
RA   Hsuan V.W., Iida K., Karnes M., Khan S., Koesema E., Ishida J., Jiang P.X.,
RA   Jones T., Kawai J., Kamiya A., Meyers C., Nakajima M., Narusaka M.,
RA   Seki M., Sakurai T., Satou M., Tamse R., Vaysberg M., Wallender E.K.,
RA   Wong C., Yamamura Y., Yuan S., Shinozaki K., Davis R.W., Theologis A.,
RA   Ecker J.R.;
RT   "Empirical analysis of transcriptional activity in the Arabidopsis
RT   genome.";
RL   Science 302:842-846(2003).
RN   [6]
RP   FUNCTION.
RX   PubMed=11607555; DOI=10.1073/pnas.92.14.6602;
RA   Delaney T.P., Friedrich L., Ryals J.A.;
RT   "Arabidopsis signal transduction mutant defective in chemically and
RT   biologically induced disease resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6602-6606(1995).
RN   [7]
RP   FUNCTION.
RX   PubMed=9002272; DOI=10.1094/mpmi.1997.10.1.69;
RA   Shah J., Tsui F., Klessig D.F.;
RT   "Characterization of a salicylic acid-insensitive mutant (sai1) of
RT   Arabidopsis thaliana, identified in a selective screen utilizing the SA-
RT   inducible expression of the tms2 gene.";
RL   Mol. Plant Microbe Interact. 10:69-78(1997).
RN   [8]
RP   INTERACTION WITH TGA FACTORS.
RX   PubMed=10659709; DOI=10.1094/mpmi.2000.13.2.191;
RA   Zhou J.-M., Trifa Y., Silva H., Pontier D., Lam E., Shah J., Klessig D.F.;
RT   "NPR1 differentially interacts with members of the TGA/OBF family of
RT   transcription factors that bind an element of the PR-1 gene required for
RT   induction by salicylic acid.";
RL   Mol. Plant Microbe Interact. 13:191-202(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TGA FACTORS.
RX   PubMed=10662863; DOI=10.2307/3870928;
RA   Despres C., DeLong C., Glaze S., Liu E., Fobert P.R.;
RT   "The Arabidopsis NPR1/NIM1 protein enhances the DNA binding activity of a
RT   subgroup of the TGA family of bZIP transcription factors.";
RL   Plant Cell 12:279-290(2000).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11148282; DOI=10.1105/tpc.12.12.2339;
RA   Kinkema M., Fan W., Dong X.;
RT   "Nuclear localization of NPR1 is required for activation of PR gene
RT   expression.";
RL   Plant Cell 12:2339-2350(2000).
RN   [11]
RP   INTERACTION WITH NIMIN-1; NIMIN-2 AND NIMIN-3.
RX   PubMed=11442055; DOI=10.1023/a:1010652620115;
RA   Weigel R.R., Baeuscher C., Pfitzner A.J.P., Pfitzner U.M.;
RT   "NIMIN-1, NIMIN-2 and NIMIN-3, members of a novel family of proteins from
RT   Arabidopsis that interact with NPR1/NIM1, a key regulator of systemic
RT   acquired resistance in plants.";
RL   Plant Mol. Biol. 46:143-160(2001).
RN   [12]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-82 AND
RP   CYS-216.
RX   PubMed=12837250; DOI=10.1016/s0092-8674(03)00429-x;
RA   Mou Z., Fan W., Dong X.;
RT   "Inducers of plant systemic acquired resistance regulate NPR1 function
RT   through redox changes.";
RL   Cell 113:935-944(2003).
RN   [13]
RP   FUNCTION.
RX   PubMed=12615947; DOI=10.1105/tpc.009159;
RA   Spoel S.H., Koornneef A., Claessens S.M., Korzelius J.P., Van Pelt J.A.,
RA   Mueller M.J., Buchala A.J., Metraux J.P., Brown R., Kazan K.,
RA   Van Loon L.C., Dong X., Pieterse C.M.;
RT   "NPR1 modulates cross-talk between salicylate- and jasmonate-dependent
RT   defense pathways through a novel function in the cytosol.";
RL   Plant Cell 15:760-770(2003).
RN   [14]
RP   FUNCTION.
RX   PubMed=12897257; DOI=10.1105/tpc.012211;
RA   Johnson C., Boden E., Arias J.;
RT   "Salicylic acid and NPR1 induce the recruitment of trans-activating TGA
RT   factors to a defense gene promoter in Arabidopsis.";
RL   Plant Cell 15:1846-1858(2003).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH TGA1 AND TGA4.
RX   PubMed=12953119; DOI=10.1105/tpc.012849;
RA   Despres C., Chubak C., Rochon A., Clark R., Bethune T., Desveaux D.,
RA   Fobert P.R.;
RT   "The Arabidopsis NPR1 disease resistance protein is a novel cofactor that
RT   confers redox regulation of DNA binding activity to the basic
RT   domain/leucine zipper transcription factor TGA1.";
RL   Plant Cell 15:2181-2191(2003).
RN   [16]
RP   DOMAIN BTB.
RX   PubMed=15749712; DOI=10.1074/jbc.m413247200;
RA   Gingerich D.J., Gagne J.M., Salter D.W., Hellmann H., Estelle M., Ma L.,
RA   Vierstra R.D.;
RT   "Cullins 3a and 3b assemble with members of the broad
RT   complex/tramtrack/bric-a-brac (BTB) protein family to form essential
RT   ubiquitin-protein ligases (E3s) in Arabidopsis.";
RL   J. Biol. Chem. 280:18810-18821(2005).
RN   [17]
RP   S-NITROSYLATION AT CYS-156.
RX   PubMed=18635760; DOI=10.1126/science.1156970;
RA   Tada Y., Spoel S.H., Pajerowska-Mukhtar K., Mou Z., Song J., Wang C.,
RA   Zuo J., Dong X.;
RT   "Plant immunity requires conformational changes of NPR1 via S-nitrosylation
RT   and thioredoxins.";
RL   Science 321:952-956(2008).
RN   [18]
RP   PHOSPHORYLATION AT SER-11 AND SER-15, MUTAGENESIS OF SER-11 AND SER-15,
RP   UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=19490895; DOI=10.1016/j.cell.2009.03.038;
RA   Spoel S.H., Mou Z., Tada Y., Spivey N.W., Genschik P., Dong X.;
RT   "Proteasome-mediated turnover of the transcription coactivator NPR1 plays
RT   dual roles in regulating plant immunity.";
RL   Cell 137:860-872(2009).
RN   [19]
RP   FUNCTION, MUTAGENESIS OF CYS-82, INTERACTION WITH CUL3A; NPR2; NPR3 AND
RP   NPR4, AND INDUCTION BY PSEUDOMONAS SYRINGAE.
RC   STRAIN=cv. Columbia;
RX   PubMed=22699612; DOI=10.1038/nature11162;
RA   Fu Z.Q., Yan S., Saleh A., Wang W., Ruble J., Oka N., Mohan R., Spoel S.H.,
RA   Tada Y., Zheng N., Dong X.;
RT   "NPR3 and NPR4 are receptors for the immune signal salicylic acid in
RT   plants.";
RL   Nature 486:228-232(2012).
RN   [20]
RP   FUNCTION, SUMOYLATION, PHOSPHORYLATION AT SER-55 AND SER-59, MUTAGENESIS OF
RP   SER-11; SER-15; SER-55; SER-59 AND LEU-346, AND INTERACTION WITH NIMIN-1;
RP   NIMIN-2; NIMIN-3; TGA3; WRKY70; SUMO3; NPR3 AND NPR4.
RC   STRAIN=cv. Columbia;
RX   PubMed=26269953; DOI=10.1016/j.chom.2015.07.005;
RA   Saleh A., Withers J., Mohan R., Marques J., Gu Y., Yan S., Zavaliev R.,
RA   Nomoto M., Tada Y., Dong X.;
RT   "Posttranslational modifications of the master transcriptional regulator
RT   NPR1 enable dynamic but tight control of plant immune responses.";
RL   Cell Host Microbe 18:169-182(2015).
RN   [21]
RP   INTERACTION WITH NPR4, AND SALICYLATE BINDING.
RC   STRAIN=cv. Columbia;
RX   PubMed=32788727; DOI=10.1038/s41586-020-2596-y;
RA   Wang W., Withers J., Li H., Zwack P.J., Rusnac D.V., Shi H., Liu L.,
RA   Yan S., Hinds T.R., Guttman M., Dong X., Zheng N.;
RT   "Structural basis of salicylic acid perception by Arabidopsis NPR
RT   proteins.";
RL   Nature 586:311-316(2020).
RN   [22] {ECO:0007744|PDB:7MK2, ECO:0007744|PDB:7MK3, ECO:0007744|PDB:7TAC, ECO:0007744|PDB:7TAD}
RP   X-RAY CRYSTALLOGRAPHY (3.06 ANGSTROMS) OF 39-410 IN COMPLEX WITH ZINC AND
RP   TGA3 IN THE PRESENCE OF DNA, FUNCTION, MUTAGENESIS OF LEU-49; PHE-53;
RP   VAL-56; CYS-82; VAL-83; CYS-150; 151-ALA-ASP-152; CYS-155; CYS-156;
RP   HIS-157; CYS-160; LEU-281; LEU-284; HIS-334; LEU-346; LEU-393 AND ILE-397,
RP   ZINC FINGER, SUBUNIT, AND INTERACTION WITH CUL3A AND TGA3.
RX   PubMed=35545668; DOI=10.1038/s41586-022-04699-w;
RA   Kumar S., Zavaliev R., Wu Q., Zhou Y., Cheng J., Dillard L., Powers J.,
RA   Withers J., Zhao J., Guan Z., Borgnia M.J., Bartesaghi A., Dong X.,
RA   Zhou P.;
RT   "Structural basis of NPR1 in activating plant immunity.";
RL   Nature 605:561-566(2022).
CC   -!- FUNCTION: Salicylic acid (SA)-binding substrate-specific adapter of an
CC       E3 ubiquitin-protein ligase complex (CUL3-RBX1-BTB) which mediates the
CC       ubiquitination and subsequent proteasomal degradation of target
CC       proteins (By similarity). Transcription cofactor that represses gene
CC       expression in the absence of salicylic acid (SA), when attached to
CC       negative cis-elements (W-box) with WRKY transcription factors (e.g.
CC       WRKY70), but stimulates gene expression upon activation by SA, when
CC       sumoylated and attached to positive cis-elements (as-1) with TGA
CC       transcription factors (e.g. TGA3), thus confering immunity through a
CC       series of gene regulations ending in a significant increase in
CC       antimicrobial and defense genes expression (e.g. PR-1 and PR-2)
CC       (PubMed:26269953, PubMed:35545668). Binds to SA with low capacity; this
CC       leads to conformational changes (PubMed:32788727, PubMed:35545668). Key
CC       positive regulator of the SA-dependent signaling pathway that
CC       negatively regulates jasmonic acid (JA)-dependent signaling pathway.
CC       Controls the onset of systemic acquired resistance (SAR). Upon SAR
CC       induction, a biphasic change in cellular reduction potential occurs,
CC       resulting in reduction of the cytoplasmic oligomeric form to dimeric
CC       and monomeric forms, which accumulate in the nucleus and activate gene
CC       expression (PubMed:35545668). Appears to control lesion expansion by
CC       acting as an inhibitor of programmed cell death (PCD) during effector-
CC       triggered immunity (ETI) that occurs in response to incompatible
CC       interaction with avirulent pathogenic bacteria (i.e. Pseudomonas
CC       syringae ES4326/avrRpt2) ending in a hypersensitive response (HR)
CC       (PubMed:22699612). Phosphorylated form is target of proteasome
CC       degradation. {ECO:0000250|UniProtKB:O22286,
CC       ECO:0000250|UniProtKB:Q5ICL9, ECO:0000269|PubMed:11607555,
CC       ECO:0000269|PubMed:12615947, ECO:0000269|PubMed:12837250,
CC       ECO:0000269|PubMed:12897257, ECO:0000269|PubMed:12953119,
CC       ECO:0000269|PubMed:22699612, ECO:0000269|PubMed:26269953,
CC       ECO:0000269|PubMed:32788727, ECO:0000269|PubMed:35545668,
CC       ECO:0000269|PubMed:9002272, ECO:0000269|PubMed:9019406}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000250|UniProtKB:O22286}.
CC   -!- SUBUNIT: Homodimer (PubMed:35545668). Oligomer of dimers in an
CC       uninduced quiescent state; disulfide-linked (PubMed:35545668). Forms
CC       activated (i.e. sumoylated) homodimers and monomers upon systemic
CC       acquired resistance (SAR) induction (PubMed:12837250, PubMed:35545668).
CC       Interacts with TGA1, TGA3, TGA4, TGA5, TGA6, TGA7 and with reduced
CC       forms of TGA1 and TGA4 (PubMed:10659709, PubMed:10662863,
CC       PubMed:12953119, PubMed:26269953). Activated homodimer binds two TGA3
CC       dimers in the presence of DNA via its ANK 2 repeat (265-295), thus
CC       forming a TGA3(2)-NPR1(2)-TGA3(2) complex in which NPR1 serves as a
CC       transcription cofactor by bridging two transcription factor complexes
CC       in an enhanceosome (PubMed:26269953, PubMed:35545668). Interacts with
CC       NIMIN-1 and NIMIN-3 via its C-terminal region, and with NIMIN-2 via its
CC       N-terminal region (PubMed:11442055, PubMed:26269953). Interacts with
CC       SUMO3 but not with SUMO1 and SUMO2; this interaction is required for
CC       phosphorylation at Ser-11 and Ser-15, and triggers activation by
CC       sumoylation and subsequent degradation (PubMed:26269953). Binds to NPR3
CC       and NPR4; these interactions are promoted by association of salicylic
CC       acid (SA) with NPR3, but disrupted by SA association with NPR4,
CC       probably due to conformational changes (PubMed:22699612,
CC       PubMed:26269953, PubMed:32788727). Binds to CUL3A, a core component of
CC       the cullin-RING ubiquitin ligases (CRL); this interaction requires NPR3
CC       and NPR4 (PubMed:22699612, PubMed:35545668). Interacts with NPR2
CC       independently of SA (PubMed:22699612). Binds to WRKY70 when unmodified
CC       (i.e. not sumoylated) (PubMed:26269953). {ECO:0000269|PubMed:10659709,
CC       ECO:0000269|PubMed:10662863, ECO:0000269|PubMed:11442055,
CC       ECO:0000269|PubMed:12837250, ECO:0000269|PubMed:12953119,
CC       ECO:0000269|PubMed:22699612, ECO:0000269|PubMed:26269953,
CC       ECO:0000269|PubMed:32788727, ECO:0000269|PubMed:35545668}.
CC   -!- INTERACTION:
CC       P93002; Q9ZVH4: CUL3A; NbExp=3; IntAct=EBI-1392127, EBI-531362;
CC       P93002; Q9FMI5: MHJ24.13; NbExp=3; IntAct=EBI-1392127, EBI-25518065;
CC       P93002; Q9FNZ5: NIMIN-1; NbExp=4; IntAct=EBI-1392127, EBI-541099;
CC       P93002; Q9LUA3: NIMIN-2; NbExp=5; IntAct=EBI-1392127, EBI-541107;
CC       P93002; Q9FNZ4: NIMIN-3; NbExp=5; IntAct=EBI-1392127, EBI-541115;
CC       P93002; Q9SZI3: NPR2; NbExp=2; IntAct=EBI-1392127, EBI-15987489;
CC       P93002; Q8L746: NPR3; NbExp=2; IntAct=EBI-1392127, EBI-4441365;
CC       P93002; Q5ICL9: NPR4; NbExp=3; IntAct=EBI-1392127, EBI-1392093;
CC       P93002; Q93ZX1: RFC4; NbExp=3; IntAct=EBI-1392127, EBI-4470690;
CC       P93002; Q39237: TGA1; NbExp=7; IntAct=EBI-1392127, EBI-541351;
CC       P93002; P43273: TGA2; NbExp=12; IntAct=EBI-1392127, EBI-541307;
CC       P93002; Q39234: TGA3; NbExp=9; IntAct=EBI-1392127, EBI-541366;
CC       P93002; Q39163: TGA5; NbExp=8; IntAct=EBI-1392127, EBI-541381;
CC       P93002; Q39140: TGA6; NbExp=5; IntAct=EBI-1392127, EBI-541321;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10662863,
CC       ECO:0000269|PubMed:11148282, ECO:0000269|PubMed:12837250,
CC       ECO:0000269|PubMed:26269953}. Nucleus {ECO:0000269|PubMed:10662863,
CC       ECO:0000269|PubMed:11148282, ECO:0000269|PubMed:12837250,
CC       ECO:0000269|PubMed:26269953}. Nucleus, nuclear body
CC       {ECO:0000269|PubMed:26269953}. Note=Accumulation in nucleus after
CC       induction by salicylic acid (SA) treatment or after pathogen infection
CC       (PubMed:10662863, PubMed:11148282, PubMed:12837250). Accumulates in
CC       nuclear bodies when sumoylated (PubMed:26269953).
CC       {ECO:0000269|PubMed:10662863, ECO:0000269|PubMed:11148282,
CC       ECO:0000269|PubMed:12837250, ECO:0000269|PubMed:26269953}.
CC   -!- INDUCTION: By salicylic acid (SA), benzol(1,2,3)thiadiazole-7-
CC       carbothioic acid S-methyl ester (BTH) and 2,6-dichloroisonicotinic acid
CC       (INA). During the hypersensitive response (HR) following infection with
CC       the avirulent Pseudomonas syringae strain ES4326/avrRpt2, programmed
CC       cell death (PCD) subsequent to effector-triggered immunity (ETI)
CC       results in NPR1 degradation at the site of infection, but is
CC       accompanied by NPR1 accumulation in cells surrounding the HR lesion
CC       (PubMed:22699612). {ECO:0000269|PubMed:22699612}.
CC   -!- DOMAIN: The BTB/POZ domain mediates the interaction with some component
CC       of ubiquitin ligase complexes. {ECO:0000269|PubMed:15749712}.
CC   -!- PTM: Phosphorylation at Ser-55 and Ser-59 prevents sumoylation to
CC       ensure stability and quiescence. {ECO:0000269|PubMed:26269953}.
CC   -!- PTM: Phosphorylated at Ser-11 and Ser-15 in the nucleus; facilitates
CC       its recruitment to a cullin3-based ubiquitin ligase leading to
CC       polyubiquitination and subsequent CUL3/CSN-mediated degradation
CC       (PubMed:19490895). This phosphorylation at Ser-11 and Ser-15 requires
CC       interaction with SUMO3, and promotes in turn activation by sumoylation
CC       and subsequent degradation (PubMed:26269953).
CC       {ECO:0000269|PubMed:19490895, ECO:0000269|PubMed:26269953}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:19490895}.
CC   -!- PTM: Sumoylated by SUMO3 independently of an E3 ligase to activate
CC       defense gene expression by switching from association with WRKY
CC       transcriptional repressors (e.g. WRKY70) to TGA transcriptional
CC       activators (e.g. TGA3) (PubMed:26269953). Sumoylation is inhibited by
CC       phosphorylation at Ser-55 and Ser-59, but seems to promote
CC       phosphorylation at Ser-11 and Ser-15 (PubMed:26269953). Sumoylation
CC       also triggers degradation, making immune induction transient
CC       (PubMed:26269953). {ECO:0000269|PubMed:26269953}.
CC   -!- PTM: The Cys-82-SH group reacts with Cys-216-SH of the other subunit to
CC       form an intermolecular disulfide. This disulfide might subsequently be
CC       reduced upon systemic acquired resistance (SAR) induction.
CC   -!- PTM: S-nitrosylation at Cys-156 facilitates its oligomerization.
CC       {ECO:0000269|PubMed:18635760}.
CC   -!- SIMILARITY: Belongs to the plant 'ANKYRIN-BTB/POZ' family. 'NPR1-like'
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U76707; AAC49611.1; -; mRNA.
DR   EMBL; U87794; AAB58262.1; -; Genomic_DNA.
DR   EMBL; AC066689; AAG51705.1; -; Genomic_DNA.
DR   EMBL; CP002684; AEE34220.1; -; Genomic_DNA.
DR   EMBL; AY050455; AAK91469.1; -; mRNA.
DR   EMBL; AY093992; AAM16253.1; -; mRNA.
DR   PIR; F96666; F96666.
DR   RefSeq; NP_176610.1; NM_105102.3.
DR   PDB; 7MK2; EM; 3.80 A; A/B=1-593.
DR   PDB; 7MK3; X-ray; 3.06 A; A/B=39-410.
DR   PDB; 7TAC; EM; 3.60 A; A/B=1-593.
DR   PDB; 7TAD; EM; 3.60 A; A/B=1-593.
DR   PDBsum; 7MK2; -.
DR   PDBsum; 7MK3; -.
DR   PDBsum; 7TAC; -.
DR   PDBsum; 7TAD; -.
DR   AlphaFoldDB; P93002; -.
DR   EMDB; EMD-23884; -.
DR   EMDB; EMD-25769; -.
DR   EMDB; EMD-25771; -.
DR   SMR; P93002; -.
DR   BioGRID; 27954; 16.
DR   ComplexPortal; CPX-3572; TGA2-NPR1 complex.
DR   DIP; DIP-38585N; -.
DR   FunCoup; P93002; 695.
DR   IntAct; P93002; 21.
DR   STRING; 3702.P93002; -.
DR   iPTMnet; P93002; -.
DR   PaxDb; 3702-AT1G64280.1; -.
DR   ProteomicsDB; 249048; -.
DR   EnsemblPlants; AT1G64280.1; AT1G64280.1; AT1G64280.
DR   GeneID; 842733; -.
DR   Gramene; AT1G64280.1; AT1G64280.1; AT1G64280.
DR   KEGG; ath:AT1G64280; -.
DR   Araport; AT1G64280; -.
DR   TAIR; AT1G64280; NPR1.
DR   eggNOG; KOG0504; Eukaryota.
DR   HOGENOM; CLU_034895_1_0_1; -.
DR   InParanoid; P93002; -.
DR   OMA; ENCCHVA; -.
DR   PhylomeDB; P93002; -.
DR   UniPathway; UPA00143; -.
DR   PRO; PR:P93002; -.
DR   Proteomes; UP000006548; Chromosome 1.
DR   ExpressionAtlas; P93002; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ComplexPortal.
DR   GO; GO:1901149; F:salicylic acid binding; IDA:UniProtKB.
DR   GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042742; P:defense response to bacterium; IMP:UniProtKB.
DR   GO; GO:0050832; P:defense response to fungus; IMP:TAIR.
DR   GO; GO:0106167; P:extracellular ATP signaling; IMP:TAIR.
DR   GO; GO:0009682; P:induced systemic resistance; IMP:TAIR.
DR   GO; GO:0031348; P:negative regulation of defense response; IMP:TAIR.
DR   GO; GO:0009626; P:plant-type hypersensitive response; IEA:UniProtKB-KW.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:ComplexPortal.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:1900424; P:regulation of defense response to bacterium; IMP:UniProtKB.
DR   GO; GO:2000022; P:regulation of jasmonic acid mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:2000031; P:regulation of salicylic acid mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010112; P:regulation of systemic acquired resistance; IMP:UniProtKB.
DR   GO; GO:0009617; P:response to bacterium; IMP:TAIR.
DR   GO; GO:0009408; P:response to heat; IMP:TAIR.
DR   GO; GO:0080027; P:response to herbivore; IEA:EnsemblPlants.
DR   GO; GO:0001666; P:response to hypoxia; IMP:TAIR.
DR   GO; GO:0009625; P:response to insect; IMP:TAIR.
DR   GO; GO:0009751; P:response to salicylic acid; IDA:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; IMP:TAIR.
DR   GO; GO:0009627; P:systemic acquired resistance; IEP:TAIR.
DR   GO; GO:0009862; P:systemic acquired resistance, salicylic acid mediated signaling pathway; IDA:ComplexPortal.
DR   CDD; cd18310; BTB_POZ_NPR_plant; 1.
DR   FunFam; 1.25.40.20:FF:000239; BTB/POZ domain and ankyrin repeat-containing protein NPR1; 1.
DR   FunFam; 3.30.710.10:FF:000192; Non-expressor of PR1; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   Gene3D; 3.30.710.10; Potassium Channel Kv1.1, Chain A; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR044292; NPR.
DR   InterPro; IPR021094; NPR1/NIM1-like_C.
DR   InterPro; IPR024228; NPR_central_dom.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   PANTHER; PTHR46475:SF11; REGULATORY PROTEIN NPR1; 1.
DR   PANTHER; PTHR46475; REGULATORY PROTEIN NPR3; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF11900; DUF3420; 1.
DR   Pfam; PF12313; NPR1_like_C; 1.
DR   SMART; SM00248; ANK; 2.
DR   SMART; SM00225; BTB; 1.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
DR   PROSITE; PS50097; BTB; 1.
DR   PROSITE; PS52046; ZF_C2HC_NPR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ANK repeat; Cytoplasm; Disulfide bond;
KW   Hypersensitive response; Metal-binding; Nucleus; Phosphoprotein;
KW   Plant defense; Reference proteome; Repeat; Repressor; S-nitrosylation;
KW   Transcription; Transcription regulation; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..593
FT                   /note="Regulatory protein NPR1"
FT                   /id="PRO_0000067063"
FT   DOMAIN          65..144
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   REPEAT          229..258
FT                   /note="ANK 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          265..295
FT                   /note="ANK 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          297..324
FT                   /note="ANK 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          328..357
FT                   /note="ANK 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          361..397
FT                   /note="ANK 5"
FT                   /evidence="ECO:0000255"
FT   ZN_FING         147..161
FT                   /note="C2HC NPR-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01391"
FT   REGION          387..525
FT                   /note="Salicylic acid-binding core (SBC)"
FT                   /evidence="ECO:0000250|UniProtKB:Q5ICL9"
FT   REGION          563..593
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           345..348
FT                   /note="SIM3, required fo binding to SUMO3 and subsequent
FT                   sumoylation"
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MOTIF           537..554
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        566..579
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        583..593
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         150
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01391,
FT                   ECO:0000269|PubMed:35545668, ECO:0007744|PDB:7MK3"
FT   BINDING         155
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01391,
FT                   ECO:0000269|PubMed:35545668, ECO:0007744|PDB:7MK3"
FT   BINDING         157
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01391,
FT                   ECO:0000269|PubMed:35545668, ECO:0007744|PDB:7MK3"
FT   BINDING         160
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01391,
FT                   ECO:0000269|PubMed:35545668, ECO:0007744|PDB:7MK3"
FT   BINDING         432
FT                   /ligand="salicylate"
FT                   /ligand_id="ChEBI:CHEBI:30762"
FT                   /evidence="ECO:0000250|UniProtKB:Q5ICL9"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19490895"
FT   MOD_RES         15
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19490895"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MOD_RES         59
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MOD_RES         156
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01391,
FT                   ECO:0000269|PubMed:18635760"
FT   DISULFID        82
FT                   /note="Interchain (with C-216); in linked form"
FT   DISULFID        216
FT                   /note="Interchain (with C-82); in linked form"
FT   VARIANT         93
FT                   /note="S -> N (in strain: cv. Wassilewskija)"
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   VARIANT         96
FT                   /note="A -> T (in strain: cv. Wassilewskija)"
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   VARIANT         108
FT                   /note="Missing (in strain: cv. Wassilewskija)"
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   VARIANT         268
FT                   /note="S -> W (in strain: cv. Wassilewskija)"
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   VARIANT         406
FT                   /note="Q -> P (in strain: cv. Wassilewskija)"
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   MUTAGEN         11
FT                   /note="S->A: Loss of ubiquitination and degradation, but
FT                   normal interaction with SUMO3 and subsequent sumoylation
FT                   associated with its localization to nuclear bodies; when
FT                   associated with A-15."
FT                   /evidence="ECO:0000269|PubMed:19490895,
FT                   ECO:0000269|PubMed:26269953"
FT   MUTAGEN         11
FT                   /note="S->D: Phosphomimic. Enhanced interaction with SUMO3,
FT                   and altered subsequent sumoylation and degradation
FT                   associated with its localization to nuclear bodies, as well
FT                   as increased salicylic acid (SA)-dependent interactions
FT                   with NPR3 and NPR4; when associated with D-15. Blocked
FT                   SA-dependent interactions with NPR3 and NPR4; when
FT                   associated with D-15 and D-346."
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MUTAGEN         15
FT                   /note="S->A: Loss of ubiquitination and degradation, but
FT                   normal interaction with SUMO3 and subsequent sumoylation
FT                   associated with its localization to nuclear bodies; when
FT                   associated with A-11."
FT                   /evidence="ECO:0000269|PubMed:19490895,
FT                   ECO:0000269|PubMed:26269953"
FT   MUTAGEN         15
FT                   /note="S->D: Phosphomimic. Enhanced interaction with SUMO3,
FT                   and promoted subsequent sumoylation and degradation
FT                   associated with its localization to nuclear bodies, as well
FT                   as increased salicylic acid (SA)-dependent interactions
FT                   with NPR3 and NPR4; when associated with D-11. Blocked
FT                   SA-dependent interactions with NPR3 and NPR4; when
FT                   associated with D-11 and D-346."
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MUTAGEN         49
FT                   /note="L->D: In dim; impaired dimerization and
FT                   oligomerization leading to increased nuclear accumulation,
FT                   but lost ability to activate as-1 elements-containing gene
FT                   promoters (e.g. NPR1, WRKY18, WRKY38 and WRKY62) with, as a
FT                   consequence, a compromised salicylic acid (SA)-induced
FT                   defense against Pseudomonas syringae pv. maculicola ES4326;
FT                   when associated with D-53; D-56 and K-83."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         53
FT                   /note="F->D: In dim; impaired dimerization and
FT                   oligomerization leading to increased nuclear accumulation,
FT                   but lost ability to activate as-1 elements-containing gene
FT                   promoters (e.g. NPR1, WRKY18, WRKY38 and WRKY62) with, as a
FT                   consequence, a compromised salicylic acid (SA)-induced
FT                   defense against Pseudomonas syringae pv. maculicola ES4326;
FT                   when associated with D-49; D-56 and K-83."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         55
FT                   /note="S->A: Normal binding to SUMO3 and subsequent
FT                   sumoylation associated with its localization to nuclear
FT                   bodies and elevated levels of defense genes expression
FT                   (e.g. PR1 and PR2) leading to severely retarded plant
FT                   growth; when associated with A-59."
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MUTAGEN         55
FT                   /note="S->D: Phosphomimic. Reduced SUMO3-mediated
FT                   sumoylation preventing nuclear body localization, as well
FT                   as reduced salicylic acid (SA)-dependent interactions with
FT                   NPR3 and NPR4, impaired ability to bind TGA3 but increased
FT                   interaction with WRKY70 leading to altered regulation of
FT                   defense gene transcription and increased susceptibility to
FT                   pathogenic bacteria (e.g. Pseudomonas syringae pv.
FT                   maculicola ES4326); when associated with D-59."
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MUTAGEN         56
FT                   /note="V->D: In dim; impaired dimerization and
FT                   oligomerization leading to increased nuclear accumulation,
FT                   but lost ability to activate as-1 elements-containing gene
FT                   promoters (e.g. NPR1, WRKY18, WRKY38 and WRKY62) with, as a
FT                   consequence, a compromised salicylic acid (SA)-induced
FT                   defense against Pseudomonas syringae pv. maculicola ES4326;
FT                   when associated with D-49; D-53 and K-83."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         59
FT                   /note="S->A: Normal binding to SUMO3 and subsequent
FT                   sumoylation associated with its localization to nuclear
FT                   bodies and elevated levels of defense genes expression
FT                   (e.g. PR1 and PR2) leading to severely retarded plant
FT                   growth; when associated with A-55."
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MUTAGEN         59
FT                   /note="S->D: Phosphomimic. Reduced SUMO3-mediated
FT                   sumoylation preventing nuclear body localization, as well
FT                   as reduced salicylic acid (SA)-dependent interactions with
FT                   NPR3 and NPR4, impaired ability to bind TGA3 but increased
FT                   interaction with WRKY70 leading to altered regulation of
FT                   defense gene transcription and increased susceptibility to
FT                   pathogenic bacteria (e.g. Pseudomonas syringae pv.
FT                   maculicola ES4326); when associated with D-55."
FT                   /evidence="ECO:0000269|PubMed:26269953"
FT   MUTAGEN         82
FT                   /note="C->A: Prevents oligomerization but not
FT                   homodimerization and leads to nuclear localization.
FT                   Constitutive PR1 gene expression conferring constitutive
FT                   resistance to Pseudomonas syringae pv. maculicola ES4326."
FT                   /evidence="ECO:0000269|PubMed:12837250,
FT                   ECO:0000269|PubMed:22699612, ECO:0000269|PubMed:35545668"
FT   MUTAGEN         83
FT                   /note="V->K: In dim; impaired dimerization and
FT                   oligomerization leading to increased nuclear accumulation,
FT                   but lost ability to activate as-1 elements-containing gene
FT                   promoters (e.g. NPR1, WRKY18, WRKY38 and WRKY62) with, as a
FT                   consequence, a compromised salicylic acid (SA)-induced
FT                   defense against Pseudomonas syringae pv. maculicola ES4326;
FT                   when associated with D-49; D-53 and D-56."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         150
FT                   /note="C->A: Defective interaction with TGA factors (e.g.
FT                   TGA3) and consequent disruption of transcriptional
FT                   regulatory activity."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         150
FT                   /note="C->Y: In npr1-2; loss of SAR induction, loss of
FT                   expression of PR genes and increased susceptibility to
FT                   infections. Defective interaction with TGA factors (e.g.
FT                   TGA3) and consequent disruption of transcriptional
FT                   regulatory activity."
FT                   /evidence="ECO:0000269|PubMed:35545668,
FT                   ECO:0000269|PubMed:9019406"
FT   MUTAGEN         151..152
FT                   /note="AD->PR: Defective interaction with TGA factors (e.g.
FT                   TGA3) and consequent disruption of transcriptional
FT                   regulatory activity."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         155
FT                   /note="C->A: Defective interaction with TGA factors (e.g.
FT                   TGA3) and consequent disruption of transcriptional
FT                   regulatory activity."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         155
FT                   /note="C->Y: In npr1-35; defective interaction with TGA
FT                   factors (e.g. TGA3) and consequent disruption of
FT                   transcriptional regulatory activity."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         156
FT                   /note="C->A: Impaired dimerization. Abolishes
FT                   S-nitrosylation and oligomerization."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         157
FT                   /note="H->A: Conserved ability to interact with TGA factors
FT                   (e.g. TGA3) to promote their transcriptional regulatory
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         160
FT                   /note="C->A: Defective interaction with TGA factors (e.g.
FT                   TGA3) and consequent disruption of transcriptional
FT                   regulatory activity."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         216
FT                   /note="C->A: Prevents oligomerization and leads to the
FT                   nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:12837250"
FT   MUTAGEN         281
FT                   /note="L->D: Abolished interaction with TGA3 and consequent
FT                   disruption of salicylic acid (SA)-induced PR1 gene
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         284
FT                   /note="L->D: Abolished interaction with TGA3 and consequent
FT                   disruption of salicylic acid (SA)-induced PR1 gene
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         300
FT                   /note="H->Y: In nim1-2; no induction of SAR genes
FT                   expression or disease resistance."
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   MUTAGEN         334
FT                   /note="H->Y: In npr1-1; loss of SAR induction, loss of
FT                   expression of PR genes and increased susceptibility to
FT                   infections. Impaired interaction with TGA3."
FT                   /evidence="ECO:0000269|PubMed:35545668,
FT                   ECO:0000269|PubMed:9019406"
FT   MUTAGEN         346
FT                   /note="L->D: In sim3; impaired interaction with SUMO3, and
FT                   altered subsequent sumoylation leading to the loss of
FT                   transcription regulation activity. Reduced salicylic acid
FT                   (SA)-dependent interactions with NPR3 and NPR4. Present in
FT                   both nucleus and cytoplasm, but not in nuclear bodies.
FT                   Reduced salicylic acid (SA)-induced PR1 and PR2 gene
FT                   expression leading to impaired SA-induced resistance
FT                   against pathogenic bacteria (e.g. Pseudomonas syringae pv.
FT                   maculicola ES4326). Impaired ability to bind to TGA3 but
FT                   enhanced interaction with WRKY70. Blocked SA-dependent
FT                   interactions with NPR3 and NPR4; when associated with D-11
FT                   and D-15."
FT                   /evidence="ECO:0000269|PubMed:26269953,
FT                   ECO:0000269|PubMed:35545668"
FT   MUTAGEN         393
FT                   /note="L->D: Reduced salicylic acid (SA)-induced PR1 gene
FT                   expression but maintained interaction with TGA3."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         397
FT                   /note="I->D: Reduced salicylic acid (SA)-induced PR1 gene
FT                   expression and impaired interaction with TGA3."
FT                   /evidence="ECO:0000269|PubMed:35545668"
FT   MUTAGEN         432
FT                   /note="R->K: In nim1-4 and nim1-5; no induction of SAR
FT                   genes expression or disease resistance."
FT                   /evidence="ECO:0000269|PubMed:9090885"
FT   HELIX           43..58
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           60..63
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   STRAND          67..70
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   STRAND          76..79
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           81..87
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           89..98
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           99..101
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   STRAND          111..113
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           114..117
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           125..137
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   TURN            145..147
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   STRAND          157..160
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           161..176
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           180..193
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   TURN            194..196
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           199..211
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           213..216
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           217..229
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           234..240
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           243..255
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           265..275
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           279..287
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           293..296
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           298..304
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           308..315
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           332..339
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           342..349
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   TURN            350..352
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           365..372
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           375..378
FT                   /evidence="ECO:0007829|PDB:7MK3"
FT   HELIX           390..403
FT                   /evidence="ECO:0007829|PDB:7MK3"
SQ   SEQUENCE   593 AA;  66032 MW;  DDD618146254CD68 CRC64;
     MDTTIDGFAD SYEISSTSFV ATDNTDSSIV YLAAEQVLTG PDVSALQLLS NSFESVFDSP
     DDFYSDAKLV LSDGREVSFH RCVLSARSSF FKSALAAAKK EKDSNNTAAV KLELKEIAKD
     YEVGFDSVVT VLAYVYSSRV RPPPKGVSEC ADENCCHVAC RPAVDFMLEV LYLAFIFKIP
     ELITLYQRHL LDVVDKVVIE DTLVILKLAN ICGKACMKLL DRCKEIIVKS NVDMVSLEKS
     LPEELVKEII DRRKELGLEV PKVKKHVSNV HKALDSDDIE LVKLLLKEDH TNLDDACALH
     FAVAYCNVKT ATDLLKLDLA DVNHRNPRGY TVLHVAAMRK EPQLILSLLE KGASASEATL
     EGRTALMIAK QATMAVECNN IPEQCKHSLK GRLCVEILEQ EDKREQIPRD VPPSFAVAAD
     ELKMTLLDLE NRVALAQRLF PTEAQAAMEI AEMKGTCEFI VTSLEPDRLT GTKRTSPGVK
     IAPFRILEEH QSRLKALSKT VELGKRFFPR CSAVLDQIMN CEDLTQLACG EDDTAEKRLQ
     KKQRYMEIQE TLKKAFSEDN LELGNSSLTD STSSTSKSTG GKRSNRKLSH RRR
//
